Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 2 of 2 for:    ebselen | covid

SPI-1005 Treatment in Moderate COVID-19 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04484025
Recruitment Status : Enrolling by invitation
First Posted : July 23, 2020
Last Update Posted : November 8, 2022
Information provided by (Responsible Party):
Sound Pharmaceuticals, Incorporated

Brief Summary:
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19 disease.

Condition or disease Intervention/treatment Phase
Covid19 Corona Virus Infection Coronavirus Coronavirus Infection Drug: Ebselen Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients
Actual Study Start Date : October 12, 2021
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SPI-1005 400 mg BID
Oral administration of SPI-1005 400 mg BID for 7 days, with 30-day follow-up
Drug: Ebselen
Glutathione peroxidase mimetic
Other Name: SPI-1005

Experimental: SPI-1005 800 mg BID
Oral administration of SPI-1005 800 mg BID for 7 days, with 30-day follow-up
Drug: Ebselen
Glutathione peroxidase mimetic
Other Name: SPI-1005

Placebo Comparator: Placebo
Oral administration of matching placebo BID for 7 days, with 30-day follow-up
Drug: Placebo
Matching placebo containing excipients

Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. WHO Ordinal Scale [ Time Frame: 30 days ]
    Clinical outcome assessed by WHO Ordinal Scale for Clinical Improvement. Scale is 0-8 where higher score is worse outcome.

  2. Degree of supplemental oxygen [ Time Frame: 30 days ]
    Respiratory status assessed by degree of supplemental oxygen (e.g. mask oxygen, mechanical ventilation)

  3. Peripheral Oxygen Saturation (SpO2) [ Time Frame: 30 days ]
    Peripheral oxygen saturation measured by pulse oximetry

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults ≥18 years of age
  • Positive nCoV2 PCR test by nasopharyngeal, oral, saliva, or respiratory sample
  • Clinical signs, symptoms, and respiratory status consistent with moderate COVID-19
  • Score of 3-4 on the WHO Ordinal Scale
  • Onset of moderate COVID-19 symptoms ≤3 days of study enrollment
  • Subject is in-patient at time of randomization to study treatment
  • Subject or legally authorized representative is willing and able to provide informed consent, and agrees for subject to comply with planned study procedures including reproductive requirements.

Exclusion Criteria:

  • Female patients who are pregnant or breastfeeding.
  • Participation in another interventional investigational drug or device study concurrently or within 30 days prior to study consent.
  • Patients with impaired hepatic or renal function.
  • Subject has any other illness or condition that, in the opinion of the investigator, would prohibit the subject from participating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04484025

Layout table for location information
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06510
United States, Idaho
St. Luke's Cystic Fibrosis Center of Idaho
Boise, Idaho, United States, 83702
United States, Kansas
Kansas University Medical Center
Kansas City, Kansas, United States, 66160
United States, Missouri
Washington University in St. Louis
Saint Louis, Missouri, United States, 63130
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Wake Forest University
Winston-Salem, North Carolina, United States, 27109
United States, Texas
University of Texas Southwestern
Dallas, Texas, United States, 75390
Sponsors and Collaborators
Sound Pharmaceuticals, Incorporated
Layout table for investigator information
Principal Investigator: Miriam Treggiari, MD Yale University

Layout table for additonal information
Responsible Party: Sound Pharmaceuticals, Incorporated Identifier: NCT04484025    
Other Study ID Numbers: SPI-1005-291
First Posted: July 23, 2020    Key Record Dates
Last Update Posted: November 8, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sound Pharmaceuticals, Incorporated:
main protease
papain-like protease
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Coronavirus Infections
Disease Attributes
Pathologic Processes
Pneumonia, Viral
Respiratory Tract Infections
Virus Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Ulcer Agents
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Cyclooxygenase Inhibitors